182 related articles for article (PubMed ID: 1382898)
1. Abbott IMx evaluated for assay of prostate-specific antigen in serum.
Dnistrian AM; Schwartz MK; Smith CA; Nisselbaum JS; Fair WR
Clin Chem; 1992 Oct; 38(10):2140-2. PubMed ID: 1382898
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Abbott IMx automated immunoassay of prostate-specific antigen.
Vessella RL; Noteboom J; Lange PH
Clin Chem; 1992 Oct; 38(10):2044-54. PubMed ID: 1382897
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the COBAS CORE Immunoassay for measuring prostate-specific antigen (PSA)--multi-centre study results. The PSA Study Group.
Schambeck CM
Eur J Clin Chem Clin Biochem; 1995 Aug; 33(8):541-7. PubMed ID: 8547440
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic significance of prostate-specific antigen velocity at intermediate PSA serum levels in relation to the standard deviation of different test systems.
Manseck A; Pilarsky C; Froschermaier S; Menschikowski M; Wirth MP
Urol Int; 1998; 60(1):25-7. PubMed ID: 9519417
[TBL] [Abstract][Full Text] [Related]
5. The analytical and clinical performance of the new Boehringer Mannheim Enzymun-Test PSA assay for prostate-specific antigen.
Blijenberg BG; Eman I; Boevé ER; Mössner E; Uhl W
Eur J Clin Chem Clin Biochem; 1995 Jun; 33(6):383-92. PubMed ID: 7578619
[TBL] [Abstract][Full Text] [Related]
6. Performance evaluation of a new chemiluminescent assay for prostate specific antigen.
Dasgupta A; Wells A; Datta P
J Clin Lab Anal; 2000; 14(4):164-8. PubMed ID: 10906769
[TBL] [Abstract][Full Text] [Related]
7. Abbott IMx and serono MAIAclone assays compared for lutropin determinations in urine.
Weiss P; Zech H; Schönholzer HP; Fritzsche H
Clin Chem; 1992 Nov; 38(11):2280-3. PubMed ID: 1424125
[TBL] [Abstract][Full Text] [Related]
8. Analytical performance and clinical validity of two free prostate-specific antigen assays compared.
Jung K; Stephan C; Lein M; Henke W; Schnorr D; Brux B; Schürenkämper P; Loening SA
Clin Chem; 1996 Jul; 42(7):1026-33. PubMed ID: 8674185
[TBL] [Abstract][Full Text] [Related]
9. Measurement of serum prostate specific antigen using IMx prostate specific antigen assay.
Klee GG; Dodge LA; Zincke H; Oesterling JE
J Urol; 1994 Jan; 151(1):94-8. PubMed ID: 7504749
[TBL] [Abstract][Full Text] [Related]
10. An analytical comparison of the three most commonly used prostate-specific antigen assays: Tandem-R, Tandem-E, and IMx.
Oesterling JE; Moyad MA; Wright GL; Beck GR
Urology; 1995 Oct; 46(4):524-32. PubMed ID: 7571222
[TBL] [Abstract][Full Text] [Related]
11. Automated determination of human choriogonadotropin by use of microparticle capture analysis.
Trundle DS; Chou PP; Raymond A
Clin Chem; 1990 Mar; 36(3):554-6. PubMed ID: 2178804
[TBL] [Abstract][Full Text] [Related]
12. Some analytical considerations on the measurement of prostate-specific antigen.
Blijenberg BG; Kranse R; Eman I; Schröder FH
Eur J Clin Chem Clin Biochem; 1996 Oct; 34(10):817-21. PubMed ID: 8933105
[TBL] [Abstract][Full Text] [Related]
13. Analytical performance of the Tandem-R free PSA immunoassay measuring free prostate-specific antigen.
Woodrum DL; French CM; Hill TM; Roman SJ; Slatore HL; Shaffer JL; York LG; Eure KL; Loveland KG; Gasior GH; Southwick PC; Shamel LB
Clin Chem; 1997 Jul; 43(7):1203-8. PubMed ID: 9216457
[TBL] [Abstract][Full Text] [Related]
14. Variation in measurement of prostate-specific antigen: importance of method and lot variability.
Wener MH; Daum PR; Brawer MK
Clin Chem; 1995 Dec; 41(12 Pt 1):1730-7. PubMed ID: 7497613
[TBL] [Abstract][Full Text] [Related]
15. Comparability of the Tandem-R and IMx assays for the measurement of serum prostate-specific antigen.
Jacobsen SJ; Lilja H; Klee GG; Wright GL; Pettersson K; Oesterling JE
Urology; 1994 Oct; 44(4):512-8. PubMed ID: 7524236
[TBL] [Abstract][Full Text] [Related]
16. SR1 assays of alpha-fetoprotein, carcinoembryonic antigen, and prostate-specific antigen compared with corresponding established commercial assays.
Jolley NL; Bacarese-Hamilton T
Clin Chem; 1994 Jun; 40(6):895-9. PubMed ID: 7522136
[TBL] [Abstract][Full Text] [Related]
17. Multicenter evaluation of the Abbott IMx CA 15-3 assay.
van Kamp GJ; Bon GG; Verstraeten RA; Lynch D; Krikau M; Flückiger J; Ruibal A; Kenemans P
Clin Chem; 1996 Jan; 42(1):28-33. PubMed ID: 8565228
[TBL] [Abstract][Full Text] [Related]
18. Methodological and clinical comparison of the ACS prostate-specific antigen assay and the Tandem-E prostate-specific antigen assay in prostate cancer.
Schambeck CM; Schmeller N; Stieber P; Jansen HM; Pahl H; Schneider W; Fateh-Moghadam A
Urology; 1995 Aug; 46(2):195-9. PubMed ID: 7542821
[TBL] [Abstract][Full Text] [Related]
19. Comparability of serum prostate-specific antigen measurement between the hybritech Tandem-R and Abbott AxSYM assays.
Leewansangtong S; Goktas S; Lepoff R; Holthaus K; Crawford ED
Urology; 1998 Sep; 52(3):467-9. PubMed ID: 9730462
[TBL] [Abstract][Full Text] [Related]
20. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays.
Zhou AM; Tewari PC; Bluestein BI; Caldwell GW; Larsen FL
Clin Chem; 1993 Dec; 39(12):2483-91. PubMed ID: 7504592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
